Tocilizumab for thyroid eye disease
What was the aim of this review? 
The aim of this review was to find out if tocilizumab is helpful for the treatment of thyroid eye disease (TED). Cochrane researchers searched for studies to answer this question and found no relevant studies. 
Key messages 
At present, there is no evidence from well‐designed studies to show that tocilizumab works, and has no side effects, for people with TED. 
What was studied in this review? 
TED is a common condition. TED is an autoimmune disease which means that a person's own immune system attacks and damages the eye and eye socket (orbit). Current treatments for TED include glucocorticosteroids, radiation and surgery. These treatments may have significant undesirable side effects. Tocilizumab is a drug that suppresses the immune system. It is used to treat other autoimmune diseases such as rheumatoid arthritis and systemic juvenile idiopathic arthritis. Tocilizumab has been used to treat people with TED and there are reports that it works. 
What are the main results of the review? 
The Cochrane researchers found no completed studies that met the standard to be included in this review. 
How up‐to‐date is this review? 
The Cochrane researchers searched for studies published up to 31 July 2018.
